Business Wire

Mobileum and Telkomsel Partner to Deliver Scalable, AI-Powered Insights for Indonesian Enterprises

10.9.2025 10:00:00 EEST | Business Wire | Press release

Share

Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and PT Telekomunikasi Selular (“Telkomsel”), the leading digital telecommunication service provider in Indonesia and Southeast Asia region, today announced a strategic partnership to deliver high-impact, AI data-driven solutions that help Indonesian enterprises unlock growth, drive innovation, and improve operational efficiency.

The partnership combines Mobileum’s expertise in transforming massive, complex telco data insights, into real-time, multi-dimensional AI insights with Telkomsel’s leadership in driving Indonesia’s digital transformation. By leveraging Telkomsel’s customer-centric B2C services and innovative B2B offerings, including IoT and Big Data, the collaboration empowers cross-sector innovation. Together, the companies will equip enterprises, including SuperApp providers and digital service platforms, with the intelligence to personalize experiences, optimize engagement, and scale effectively in a dynamic market.

Creating value for Indonesian enterprises

Enterprise customers will gain access to real-time market intelligence, behavioral analytics, and flexible commercial models – delivered through responsible, insight-driven solutions that support strategic decision-making and align with evolving data governance standards.

Initial focus areas include:

  • Market share insights for ride-hailing, food delivery, EV, and mobile banking apps
  • Behavioral analytics across video, ecommerce, travel, health, and education platforms
  • Smart home and broadband user profiling for next-generation digital services

“Today’s enterprises, especially digital-first players like SuperApp providers, need real-time, multi-dimensional insights to stay ahead,” said Raja Hussain, Chief Revenue Officer of Mobileum. “Through this partnership, Telkomsel leverages Mobileum’s AI-powered analytics engine to process telco data insights within a controlled and secure environment, ensuring full compliance with local data sovereignty principles that helps businesses improve engagement, benchmark performance, and deliver more personalized experiences.”

“At Telkomsel, we are committed to accelerating Indonesia’s digital ecosystem by equipping businesses with the innovative and impactful solutions they need to thrive,” said Telkomsel’s Vice President Data Solutions and Digital Financial Services, Alfian Manullang. “This partnership enhances our ability to provide timely, AI data-driven insights that help enterprises innovate faster, operate more efficiently, and uncover new opportunities for sustainable growth. By combining our leadership in building an inclusive, competitive digital society with Mobileum’s advanced analytics capabilities, we’re delivering measurable value that empowers businesses today while helping shape a brighter digital future for Indonesia.”

Powered by Mobileum’s DNA platform

The collaboration is built on Mobileum’s Deep Network Analytics (DNA) platform, which uses machine learning and geo-analytics models to unlock the hidden value of operator’s network data. Designed to inform strategic decision-making, DNA delivers granular, real-time insights into customer behavior, market trends, and application engagement. Mobileum DNA enables enterprises to launch targeted campaigns, identify new revenue opportunities, and establish digital partnerships – all while upholding data privacy standards and maximizing marketing return on investment.

About Mobileum Inc.

Mobileum is a leading provider of Telecom analytics solutions for roaming, core network, security, risk management, domestic and international connectivity testing, and customer intelligence. More than 1,000 customers rely on its Active Intelligence platform, which provides advanced analytics solutions, allowing customers to connect deep network and operational intelligence with real-time actions that increase revenue, improve customer experience, and reduce costs. Headquartered in Silicon Valley, Mobileum has global offices in Australia, Germany, Greece, India, Japan, Portugal, Singapore, UK, and United Arab Emirates.

Learn more in https://www.mobileum.com/.

About Telkomsel

Telkomsel is the region’s leading digital telecommunications service provider, committed to empowering Indonesian society to be highly competitive and creating a bright future by providing connectivity, innovative and superior services, and solutions for everyone, every home, and every business, thus opening up all possibilities. Aligned with the spirit of digitizing Indonesia, Telkomsel acts as the largest convergence service provider, consistently expanding its 4G network that now covers 97% of the population. As the pioneer of 5G commercialization in Indonesia, Telkomsel affirms its position as the leading and most expansive 5G operator with more than 3,000 5G BTS units. Telkomsel also implements the latest technology, utilizing end-to-end implementation of Artificial Intelligence (AI)-powered Autonomous Network, to enhance service quality and customer experience, while continuing to develop digital services such as Digital Lifestyle, Digital Advertising, Digital Enterprise Solutions, and the Internet of Things. Throughout its 30 years of history, Telkomsel now operates more than 280,434 BTS, serving over 158.4 million mobile customers, and more than 10 million fixed broadband (IndiHome) customers nationwide. In its commitment to sustainable operations, Telkomsel adheres to ESG principles to create a positive impact on its ecosystem. For more detailed information and customer services, please visit www.telkomsel.com, follow us on Facebook at facebook.com/Telkomsel, Twitter ”X” @telkomsel, and Instagram @telkomsel, or connect with our virtual assistant through the MyTelkomsel app.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250910376923/en/

Contacts

Useful Contacts:

QUEXOR GROUP INC.
Cheryl Fritz | cfritz@quexor.com | Mob.: +1 (703) 856-5932

Media and Corporate Communications – Mobileum
Sandra Almeida | sandra.almeida@mobileum.com | Mob. +351 939650229

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye